下载文档原格式
论著·社区中医药CHINESE COMMUNITY DOCTORS 中国社区医师2020年第36卷第22期腹胀作为临床常见的症状，是影响晚期恶性肿瘤患者生活质量的重要因素之一，虽然腹胀并没有统一的诊断及评价标准，但是对患者、家属以及医生都会造成许多困扰。
现在肿瘤领域的研究主要集中在针对肿瘤疾病本身的研究，而对恶性肿瘤并发症的一些问题，并没有给予足够的关注，虽然临床针对晚期恶性肿瘤的一些症状群有研究，如疼痛-苦恼-疲乏、恶心-食欲不振-呕吐以及睡眠不安-健忘-悲伤等，而针对腹胀问题的研究相对较少，但是不能不正视它对晚期恶性肿瘤患者所造成的危害，因此，我们有必要开展一些相关的临床研究，以期能缓解这一问题对患者造成的伤害，提高患者的生活质量。
首先晚期腹部恶性肿瘤患者腹胀的原因较复杂，但主要为恶性肿瘤腹膜转移导致的腹水，及胃肠功能障碍导致的胀气两大原因居多，从中医角度来看，主要为气机不畅，水道不通，如余俊仁，在加味六磨汤敷脐治疗恶性肠梗阻的临床疗效观察[1]、付晓峰[2]在当归芍药散加味治疗肝脾血瘀型恶性腹水临床观察中均阐释了上述病机。
中药散剂或膏剂外敷，作为常用的中医治法之一，在恶性肿瘤的治疗中具有重要的地位，如秦传蓉等[3]采用中医外治法在恶性肿瘤治疗中的研究进展、苏菲等[4]在中医外治法在晚期肿瘤胸腹腔积液患者中的应用进展中均有相关总结。
而复方大黄软膏的主要作用机理即行气消胀、通调水道。
复方大黄软膏系我院院内制剂“七消散”的膏剂，有比较长的院内应用经验，最初是用于治疗急性胰腺炎，在张帆等[5]运用七消散外敷治疗急性胰腺炎的疗效观察中，辅用七消散能更快的缓解腹胀、腹痛等症状，减少并发症发生，缩短住院时间；这一研究也为我院将七消散制成院内制剂打下了基础。
而为了方便临床的应用，皮凤娟等[6]将七消散制成了膏剂，取名复方大黄软膏，为了保证质量，分别复方大黄软膏外敷治疗晚期腹部恶性肿瘤患者腹胀的临床研究张彬646000泸州市中医医院，四川泸州doi:10.3969/j.issn.1007-614x.2020.22.043基金项目2017年泸州市科技局科技计划项目/泸州市卫计委科研课题[2017-S-46(2/2)]摘要目的：探讨复方大黄软膏外敷对晚期腹部恶性肿瘤患者腹胀的疗效及安全性。
药物与临床DOI：10.16662/ki.1674-0742.2023.30.103注射用重组人脑利钠肽联合左西孟旦治疗重症顽固性心力衰竭的临床效果分析独步原，丁大胜，马常乐新沂市人民医院心内二科江苏新沂221400［摘要］目的分析重症顽固性心力衰竭（refractory heart failure, RHF）治疗中左西孟旦+重组人脑利钠肽（注射用）的作用。
方法随机选择2020年1月—2023年7月在新沂市人民医院接受治疗的70例重症RHF患者，以随机数表法分为两组，35例/组，以重组人脑利钠肽（注射用）治疗的纳入对照组，在对照组基础上加用左西孟旦治疗的划入观察组。
对比两组患者疗效、心功能指标、心肌损伤标志物及不良反应。
结果观察组总有效率为97.14%，较对照组的77.14%高，差异有统计学意义（χ2=4.590，P<0.05）。
治疗后，观察组左心室射血分数高于对照组，左室后壁厚度、心室间隔厚度、左室舒张期内径低于对照组，差异有统计学意义（P<0.05）。
观察组心肌肌钙蛋白I、N末端B型脑钠肽前体均低于对照组，差异有统计学意义（P<0.05）。
两组患者不良反应发生率比较，差异无统计学意义（P>0.05）。
结论重组人脑利钠肽+左西孟旦治疗重症RHF效果确切，心功能改善明显，且可保障药效与安全性。
［关键词］顽固性心力衰竭；重组人脑利钠肽；左西孟旦；不良反应［中图分类号］R453 ［文献标识码］A ［文章编号］1674-0742（2023）10(c)-0103-04Clinical Effect of Recombinant Human Brain Natriuretic Peptide for Injec⁃tion Combined with Levosimendan in the Treatment of Severe Refractory Heart FailureDU Buyuan, DING Dasheng, MA ChangleDepartment of Cardiology II, Xinyi People's Hospital, Xinyi, Jiangsu Province, 221400 China[Abstract] Objective To analyze the effects of levosimendan + recombinant human brain natriuretic peptide (inject⁃able) in the treatment of critical refractory heart failure (RHF).Methods70 patients with severe RHF who received treatment in Xinyi People's Hospital from January 2020 to July 2023 were randomly selected and divided into two groups by random number table, with 35 cases/group. Those treated with recombinant human brain natriuretic peptide (for injection) were included in the control group, and those treated with levosimendan on the basis of the control group were included in the observation group. The efficacy, cardiac function indexes, myocardial injury markers and adverse reactions were compared between the two groups.Results The total effective rate of the observation group was 97.14%, which was higher than that of the control group (77.14%), and the difference was statistically significant (χ2= 4.590, P<0.05). After treatment, the left ventricular ejection fraction in the observation group was higher than that in the control group, and the left ventricular posterior wall thickness, interventricular septum thickness, and left ventricu⁃lar end-diastolic diameter were lower than those in the control group, and the difference was statistically significant (P <0.05). Myocardial troponin I and N-terminal B-type brain natriuretic peptide precursors in the observation group were lower than those in the control group, and the difference was statistically significant (P<0.05). There was no sta⁃tistically significant difference in the incidence of adverse reactions between the two groups (P>0.05).Conclusion Re⁃combinant human brain natriuretic peptide plus levosimendan is effective in the treatment of severe RHF, with obvi⁃ous improvement in cardiac function, and can ensure efficacy and safety.[Key words] Refractory heart failure; Recombinant human brain natriuretic peptide; Levosimendan; Adverse reaction [作者简介] 独步原（1986-），女，本科，主治医师，研究方向为心内科临床。
人凝血因子检验方法引言人凝血因子是一组在血液凝固过程中起关键作用的蛋白质。
凝血因子检验是评估一个人的凝血功能是否正常的重要方法。
本文将介绍人凝血因子检验的方法，包括常用的实验室检测方法和新兴的分子诊断技术。
1. 凝血因子简介人体内共有13种已知的凝血因子，它们按照其参与凝血反应的顺序被编号为Ⅰ至ⅩⅢ。
这些凝血因子在正常情况下相互协作，形成一个复杂而精确的平衡系统，以维持正常的止血和溶栓过程。
2. 常用实验室检测方法2.1 凝血酶原时间（PT）PT是评估外源性凝血通路功能的指标。
该测试使用钠柠檬酸抗凝剂处理患者的血液样本，然后添加磷酸钙和组织因子来启动凝血反应。
通过计算患者样本中形成凝块所需时间来确定PT值。
2.2 部分凝血活酶时间（APTT）APTT是评估内源性凝血通路功能的指标。
该测试使用钠柠檬酸抗凝剂处理患者的血液样本，然后添加磷酸钙和活化的部分凝血活酶来启动凝血反应。
通过计算患者样本中形成凝块所需时间来确定APTT值。
2.3 血小板计数和出血时间除了凝血因子本身，血小板也是维持正常止血过程中不可或缺的组成部分。
进行完整的凝血功能检查时，还需要评估患者的血小板计数和出血时间。
3. 分子诊断技术近年来，随着分子生物学技术的不断发展，越来越多的新兴检测方法被应用于人凝血因子检验中。
3.1 多重PCR多重PCR（Polymerase Chain Reaction）是一种高效且灵敏的分子生物学技术，可以同时检测多个基因突变。
在人凝血因子检验中，多重PCR可以用于快速筛查常见突变引起的凝血因子缺陷。
3.2 基因测序基因测序是一种直接测定DNA序列的方法。
通过对凝血因子相关基因进行全序列测定，可以发现罕见突变或新的基因变异，为凝血功能异常的诊断提供更准确的依据。
3.3 基因芯片技术基因芯片技术是一种高通量的基因分析方法，可以同时检测上千个基因。
在人凝血因子检验中，基因芯片技术可以用于快速筛查多个凝血相关基因的变异。
大黄芒硝外敷在会阴水肿的应用研究发布时间：2022-06-08T12:00:11.072Z 来源：《中国医学人文》2022年1月1期作者：周华英罗文婷[导读]周华英罗文婷（昆山市第六人民医院妇产科；江苏昆山 215300）【摘要】目的：评估会阴水肿患者实施大黄芒硝外敷治疗的应用效果。
方法：对60例本医院实施治疗的会阴水肿予以项目研究，信息采集时间为2020年2月至2021年2月，以随机数字表法为分组方案，对照组（n=30常规湿敷治疗）、观察组（n=30大黄芒硝外敷治疗），统计及对比组间治疗前后指标、临床效果情况。
结果：（1）会阴水肿患者治疗前指标无组间统计学差异性（P>0.05）。
观察组的会阴水肿患者对比对照组患者治疗后疼痛、水肿评分统计指标较低，具备组间统计学差异性（P<0.05）。
（2）观察组的会阴水肿患者（96.67%）对比对照组患者（76.67%）临床效果统计指标较高，具备组间统计学差异性（P<0.05）。
结论：会阴水肿实施大黄芒硝外敷治疗效果确切，能够显著改善患者疼痛及水肿症状。
【关键词】会阴水肿；大黄；芒硝[Abstract] Objective: To evaluate the effect of external application of rhubarb Mirabilite in patients with perineal edema. Methods: 60 cases of perineal edema treated in our hospital were studied. The information collection time was from February 2020 to February 2021. Taking the random number table method as the grouping scheme, the indexes and clinical effects before and after treatment in the control group (n = 30 conventional wet compress treatment) and the observation group (n = 30 rhubarb mirabilite external application treatment) were counted and compared. Results: (1) there was no significant difference in the indexes of patients with perineal edema before treatment (P > 0.05). The statistical indexes of pain and edema scores in the observation group were lower than those in the control group (P < 0.05). (2) The patients with perineal edema in the observation group (96.67%) had higher statistical indexes of clinical effect than those in the control group (76.67%), which had statistical difference between the groups (P < 0.05). Conclusion: external application of rhubarb and mirabilite is effective in the treatment of perineal edema, which can significantly improve the symptoms of pain and edema.【 key words 】 perineal edema; chinese rhubarb; Mirabilite会阴水肿多发于分娩期间，患者因分娩损伤、胎儿体重较大、孕程时间长等因素的共同影响，发生会因为只水肿、疼痛症状[1]。
中药活血化瘀汤治疗卵巢囊肿的治疗效果发布时间：2022-04-29T02:24:18.830Z 来源：《健康世界》2022年3期作者：丛文秀[导读] 目的探讨分析对卵巢囊肿患者采用中药活血化瘀汤进行治疗的效果。
方法本次研究对象均为卵巢囊肿患者丛文秀七台河市妇幼保健院 154600【摘要】目的探讨分析对卵巢囊肿患者采用中药活血化瘀汤进行治疗的效果。
方法本次研究对象均为卵巢囊肿患者，共计80例，收治时间范围介于2020年5月到2021年11月之间。
按照双盲法对患者分组，其中40例设为甲组采用大黄蛰虫丸治疗，另外40例设为乙组采用中药活血化瘀汤进行治疗。
观察对两组的治疗效果。
结果比较两组的治疗效果，乙组优于甲组（P＜0.05）；比较两组治疗后的卵巢直径，乙组低于甲组（P＜0.05）。
结论根据本次研究的结果可以确认，对卵巢囊肿患者采用中药活血化瘀汤进行治疗的效果极为确切，能够有效控制患者的病情，改善患者的卵巢状态，值得大力推广。
【关键词】卵巢囊肿；活血化瘀汤；中医中药；治疗效果；对比分析 [Abstract] Objective To explore and analyze the effect of Huoxue Huayu Decoction on patients with ovarian cyst. Methods the subjects of this study were 80 patients with ovarian cyst. The treatment time ranged from May 2020 to November 2021. The patients were divided into groups according to the double-blind method, of which 40 cases were treated with rhubarb Zhezhuang pill in group A and 40 cases were treated with Huoxue Huayu Decoction in group B. The therapeutic effects of the two groups were observed. Results the therapeutic effects of the two groups were compared. Group B was better than group A (P < 0.05); The ovarian diameter of group B was lower than that of group A (P < 0.05). Conclusion according to the results of this study, it can be confirmed that the effect of Huoxue Huayu Decoction in the treatment of patients with ovarian cyst is very accurate. It can effectively control the patient's condition and improve the patient's ovarian state, which is worthy of vigorous promotion.【 key words 】 ovarian cyst; Huoxue Huayu Decoction; Traditional Chinese medicine; Therapeutic effect; comparative analysis 卵巢囊肿属于临床上比较常见的一种妇科疾病，患者在发病后其卵巢表面或者是内部会出现囊状结构，这将会引发患者出现下腹坠胀感等不适症状。
排毒保肾丸治疗慢性肾脏病3~4期的临床研究王水华;刘永芳;陈帮明;吴兆东;王国斌;黄红恩;魏林;钟利平【期刊名称】《中国中西医结合肾病杂志》【年(卷),期】2015(0)6【摘要】目的：观察排毒保肾丸（大黄虫丸加减）治疗慢性肾脏病（CKD）3~4期中医辨证兼血瘀证和湿浊证患者的疗效。
方法：将符合入选标准的 CKD3~4期辨证兼血瘀证和湿浊证患者284例随机分为治疗组和对照组各142例，治疗组和对照组在常规治疗的基础上分别给予排毒保肾丸和包醛氧淀粉胶囊治疗，疗程均为16周。
观察两组患者血瘀证和湿浊证中医证候的变化，以及24 h 尿蛋白定量（24 h UP）、血纤维蛋白原（Fg）、尿素氮（BUN）、肌酐（Scr）、估算肾小球滤过率（eG-FR）的改变，判定疾病疗效，记录不良反应。
结果：治疗组血瘀证和湿浊证主症、次症均得到改善（P ﹤0.05或 P ﹤0．01），中医证候总有效率分别为90．5%和58．9%（P ﹤0．01）；与治疗前比较，治疗组治疗后24 h UP 减少、血 Fg 降低（P ﹤0．01），血BUN、Scr 降低（P ﹤0．01），eGFR 升高（P ﹤0．01），对照组治疗后血 BUN 降低（P ﹤0．01），Scr 下降（P ﹤0．05）、eGFR 升高（P ﹤0．05）；与对照组治疗后比较，治疗组治疗后24 h UP、Fg、Scr 降低（P ﹤0．01），eGFR 升高（P ﹤0．01），BUN 差异无统计学意义（P ﹥0．05）；治疗组和对照组疾病总有效率分别为81．0%和69．0%（P ﹤0．01）。
结论：排毒保肾丸能改善 CKD3~4期中医辨证兼血瘀证和湿浊证患者中医证候，减少蛋白尿，降低血纤维蛋白原，降低血尿素氮和肌酐，改善肾功能。
%Objective:To observe the effect of Paidu Baoshen Pill(modified Rhubarb Zhechong Pills)in the treatment of chronic kidney disease stage 3and 4 patients whose syndrome differentiation were both with blood stasis and dampness syndrome. Methods:284 cases of chronic kidney disease stage 3 and 4 patients whose syndrome differentiation were both with blood stasis and dampness syndrome were ramdoly divided into treatment group 142 cases and control group 142 cases. On the basis of conventional therapy,the treatment group and control group were given Paidu Baoshen Pill and coated aldehyde oxystarch capsules respectively for 16 weeks. Then the changes of TCM blood stasis and dampness syndrome. Blood urea nitrogen,creatinine,estimated glomerular fil-tration rate,the 24 hours urinary protein quantitative,the fibrinogen and the adverse reactions were observed. Results:The primary and second symptoms of blood stasis and dampness in the treatment group were improved(P ﹤ 0. 05 or P ﹤ 0. 01). The total efficiency of TCM syndromes were better in the treatment group than that of the control group(P ﹤ 0. 05). Compare with the pretherapy stage, the 24 hUP reduced(P ﹤ 0. 01),the Fg,BUN and Scr decreased(P ﹤ 0.01),the eGFR ascended(P ﹤ 0. 01)in the treatment group. The BUN decreased(P ﹤ 0. 01),the Scr decreased(P ﹤ 0. 05),the eGFR elevated in the control group(P ﹤ 0. 05),when compared with the pretherapy. Compared with the posttreatment conroll group,the 24 uUP,Fb and Scr decreased,the eGFR in-creased,the BUN had no statistical significance(P ﹥ 0. 05). The total effective rate of the treatment group and the control group were 81. 0% and 69. 0% respectively(P ﹤ 0. 01). Conclusion:Paidu Baoshen Pill can improve the TCM syndrome of chronic kidney dis-ease stage 3 and 4 patients whose syndrome differentiation were both with blood stasis anddampness syndrome,decreased urine pro-tein,reduce the blood urea nitrogen and creatinine,reduced fibrinogen and improve renal function.【总页数】4页(P502-505)【作者】王水华;刘永芳;陈帮明;吴兆东;王国斌;黄红恩;魏林;钟利平【作者单位】江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000;江西省九江市中医医院肾病科九江 332000【正文语种】中文【相关文献】1.排毒保肾丸纠正慢性肾衰钙磷代谢紊乱的临床研究 [J], 时蔡林;王国斌2.保肾活血排毒法治疗早中期慢性肾脏病临床疗效评价 [J], 许陵冬;陈继红;陶兴3.排毒保肾丸联合缬沙坦对保护腹膜透析患者残余肾功能的临床研究 [J], 刘干炎;王国斌;王水华;陈帮明;黄红恩;魏林;王金象;刘永芳4.排毒保肾丸对慢性肾脏病2期患者蛋白尿的影响 [J], 陈帮明;吴慧心;刘永芳;刘晖扬;刘干炎;林雪菲;熊清玓;王金象;姚子睿;徐媖5.排毒保肾丸治疗慢性肾脏病2期临床观察 [J], 陈帮明;吴慧心;刘永芳;刘晖扬;刘干炎;林雪菲;熊清玓;王金象;姚子睿;徐媖因版权原因，仅展示原文概要，查看原文内容请购买。
■中医中葯■2018年3月中药芒硝、大黄外敷在妇科腹腔镜术后腹部瘀斑中的应用张萍(宝鸡市妇幼保健院妇1科，陕西宝鸡，721000)摘要：目的探讨中药芒硝、大黄外敷在妇科腹腔镜术后腹部瘀斑中的应用效果。
方法选取在我院行妇科腹腔镜手术后发生 腹部瘀斑的患者70例，随机将其分为观察组和对照组，各35例。
对照组行常规治疗，观察组在常规治疗的基础上应用芒硝、大黄外敷。
对比两组用药后的疼痛情况、瘀斑变浅时间和瘀斑持续时间及患者对治疗的满意度。
结果随着用药时间的推移，两组的VAS评分均降低(P<0.05);用药l、3d后，观察组的VAS评分均低于对照组(P<0.05);观察组的瘀斑变浅时间和瘀斑 持续时间均短于对照组(P<0.05);观察组患者治疗的满意度高于对照组(P<0.05)。
结论应用中药芒硝、大黄外敷治疗妇科腹 腔镜术后腹部瘀斑可有效地缓解疼痛，加快瘀斑的吸收，并可提高患者对治疗的满意度，值得临床推广。
关键词：腹部瘀斑；芒硝；大黄;腹腔镜中图分类号：R737.9 文献标志码：A 文章编号：2096-1413(2018)07-0112-02Application effect of Chinese medicine Mirabilite and Rhubarb for external use in abdominal ecchymosis after gynecologic laparoscopic surgeryZHANG Ping(No.1 Gynecology Department, Baoji Maternal and Child Care Hospital, Baoji 721000, China)A B S T R A C T:Objective To explore the clinical effects of Chinese medicine Mirabilite and Rhubarb for external use in abdominal ecchymosis after gynecologic laparoscopic surgery. Methods A total of 70 patients with abdominal ecchymosis after gynecological laparoscopic surgery in our hospital were selected and randomly divided into observation group (35 cases) and control group (35 cases). The control group received conventional treatment, while the observation group was treated with Mirabilite and Rhubarb for external use on the basis of routine treatment. The pain condition, the superficial time of ecchymosis and the duration of ecchymosis and the satisfaction of the two groups were compared. Results With the passage of time, the VAS scores of the two groups decreased (P<0.05); after 1, 3 days of medication, the VAS scores of the observation group were lower than those of the control group (P<0.05). The superficial time of ecchymosis and the duration of ecchymosis in the observation group were shorter than those in the control group (P<0.05). The satisfaction rate with treatment of the observation group was higher than that of the control group (P<0.05). Conclusion The application of Chinese medicine Mirabilite and Rhubarb for external use in abdominal ecchymosis after gynecological laparoscopic can effectively relieve pain, accelerate the absorption of ecchymosis, and improve patients' satisfaction with treatment, which is worthy of clinical promotion.K E Y W O R D S:abdominal ecchymosis; Mirabilite; Rhubarb; laparoscopic腹腔镜手术以创伤小、出血量少和术后恢复快等优点逐渐取代传统手术，成为治疗妇科疾病的首选术式。
中药大黄辅助治疗急性重症胰腺炎的临床效果观察摘要：目的：观察病探讨中药大黄辅助治疗急性重症胰腺炎的临床效果。
方法随机抽取我院2013年2月——2015年6月60例重症胰腺炎患者，根据患者治疗方法对其进行分组，其中对照组实施常规治疗方法，观察组在此基础上采用中药大黄进行辅助治疗，比较两组患者治疗情况。
结果观察组总有效率为93.1%，明显高于对照组（67.7%），两组差异明显（P＜0.05）；观察组患者病情转归情况明显优于对照组，且白细胞、甘油三酯下降程度显著优于对照组，两组差异显著（P＜0.05）。
结论在常规治疗的基础上，将中药大黄作为治疗重症急性胰腺炎的辅助措施，可明显提高治疗效果，对患者良好预后具有重要意义。
关键词：中药大黄；急性重症胰腺炎[Abstract]Objective To observe the clinical effect of disease to explore traditional Chinese medicine Rhubarb in the treatment of severe acute pancreatitis.Methods randomly selected in our hospital in 2013 February - June 2015 60 cases of severe acute pancreatitis patients，grouping the according to the treatment methods，the control group received routine treatment method，the observation group based on the use of Chinese medicine rhubarb adjunctive therapy，compared two groups of patients treatment.The results in the observation group，the total effective rate was 93.1%，significantly higher than that of the control group（67.7%），the difference between the two groups significantly（P < 0.05）；observation group patients prognosis was better than that of the control group and white blood cells，triglycerides decreased severity was significantly superior to the control group，the difference between the two groups significantly（P < 0.05）.Conclusion on the basis of routine treatment，the rhubarb as adjunct to the treatment of severe acute pancreatitis（SAP），can significantly improve curative effect，has the vital significance to the patients with good prognosis.[Key words]Rhubarb；acute severe pancreatitis；我院在对重症急性胰腺炎开展临床诊疗工作时，将中药大黄作为辅助治疗措施，取得满意疗效，现选择2013年2月——2015年6月60例重症胰腺炎患者加以说明，结果如下。
临床医学研究与实践2021年5月第6卷第13期DOI :10.19347/ki.2096-1413.202113028作者简介：崔鸿鹤（1970-），男，汉族，河南信阳人，副主任医师，学士。
研究方向：儿科疾病的诊治。
Clinical effect of atomized inhalation of interferon α2b injection in thetreatment of children with respiratory syncytial virus pneumoniaCUI Honghe(Huaibin County Third People's Hospital,Xinyang 464400,China)ABSTRACT:Objective To analyze the clinical effect of atomized inhalation of interferon α2b injection in the treatment of children with respiratory syncytial virus pneumonia.Methods A total of 100children with respiratory syncytial virus pneumonia admitted in our hospital from June 2018to June 2020were selected retrospectively.According to the treatment methods,the children were divided into conventional treatment group (n=50,conventional drugs)and atomized inhalationgroup (n=50,atomized inhalation of interferon α2b injection on the basis of conventional treatment).The levels of serum inflammatory factors,clinical efficacy,disappearance time of symptoms and signs,and occurrence of adverse reactions were compared between the two groups.Results After treatment,the levels of IL-10in the two groups were higher than that before treatment,and the levels of IL -18and TNF -αwere lower than those before treatment,and those in the atomized inhalation group were better than the conventional treatment group (P <0.05).The total effective rate of treatment of the atomized inhalation group was higher than that of the conventional treatment group (P <0.05).The disappearance time of fever,cough,wheezing and pulmonary rales in the atomized inhalation group were shorter than those in the conventional treatment group (P <0.05).There was no significant difference in the total incidence of adverse reactionsbetween the two groups (P >0.05).Conclusion The atomized inhalation of interferon α2b injection in the treatment of children with respiratory syncytial virus pneumonia has a good effect,and it will not increase the adverse reactions of children.KEYWORDS:respiratory syncytial virus pneumonia in children;atomized inhalation;interferon α2b injection;adverse reactions雾化吸入干扰素α2b 注射液治疗小儿呼吸道合胞病毒肺炎的临床效果崔鸿鹤（河南省淮滨县第三人民医院，河南信阳，464400）摘要：目的分析雾化吸入干扰素α2b 注射液治疗小儿呼吸道合胞病毒肺炎的临床效果。
海曲泊帕联合重组人血小板生成素治疗原发免疫性血小板减少症的临床观察郭星 1＊，赵丹 2，左金曼 3（1.蚌埠医学院第二附属医院药学部，安徽 蚌埠 233020；2.蚌埠市第三人民医院药学部，安徽 蚌埠 233099；3.蚌埠医学院第二附属医院血液内科，安徽 蚌埠 233020）中图分类号 R 973；R 558+.2 文献标志码 A 文章编号 1001-0408（2023）23-2910-05DOI 10.6039/j.issn.1001-0408.2023.23.17摘要 目的 探讨海曲泊帕联合重组人血小板生成素（rhTPO ）治疗原发免疫性血小板减少症（ITP ）在真实世界中的临床疗效和安全性。
方法 回顾性选取2021年1月至2022年12月蚌埠医学院第二附属医院诊断为ITP 的患者，将其中使用海曲泊帕联合rhTPO 的98例患者设为观察组，使用rhTPO 的157例患者设为对照组。
观察并比较2组患者治疗前后的血小板计数、临床疗效、出血情况、血小板输注率和不良反应发生情况。
结果 从治疗第8天[观察组为（61.04±13.46）×109 L －1，对照组为（52.11±12.06）×109 L －1]开始，2组患者的血小板计数差异有统计学意义（P ＜0.05），且2组患者血小板计数的峰值和稳定值差异均有统计学意义（P ＜0.05）。
观察组与对照组患者的总有效率分别为79.59%和66.88%，累积达终点率分别为81.32%与68.68%，中位有效时间分别为8 d 和10 d ，差异均有统计学意义（P ＜0.05）。
治疗期间观察组与对照组患者的出血率分别为3.06%和8.28%（P ＜0.05），出血等级均为1级或2级；血小板输注率分别为31.63%和40.76%，差异有统计学意义（P ＜0.05）。
2组患者不良反应发生率分别为11.22%和9.55%，差异无统计学意义（P ＞0.05），且均无中重度不良反应记录。
